Support teaching, research, and patient care.
Dr. Electron Kebebew is an internationally recognized expert in Endocrine Oncology and Surgery. He has performed more than four thousand operations on the adrenal, parathyroid, and thyroid glands, and for neuroendocrine tumors of the gastrointestinal tract and pancreas. He has given over 200 invited lectures and visiting professorships. His clinical and translational studies on endocrine and neuroendocrine tumors have been awarded more than $30 million in research funding. Dr. Kebebew has authored and coauthored over 400 scientific articles, 40 book chapters, and edited or co-edited four textbooks. His scientific contributions include the use of molecular markers in thyroid nodule to refine diagnosis and prognostication, identification of novel target for endocrine cancer therapy, implementation of genetic testing and advanced imaging modality to optimize the management of patients with endocrine neoplasm and to allow the practice of precision surgery, and the identification and characterization of inherited endocrine and neuroendocrine syndromes, and their susceptibility genes.
Dr. Kebebew’s translational and clinical investigations have three main scientific goals: 1) to develop effective therapies for fatal, rare and neglected endocrine cancers, 2) to identify new methods, strategies and technologies for improving the diagnosis and treatment of endocrine neoplasms and the prognostication of endocrine cancers, and 3) to develop methods for precision treatment of endocrine tumors.
Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)
This study will investigate the safety and efficacy of Relacorilant in combination with
Pembrolizumab for Patients with Adrenocortical Carcinoma which Produces Too Much Stress
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
View full details